Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gh Research Plc (NQ: GHRS )

12.70 +0.30 (+2.42%)
Streaming Delayed Price Updated: 10:00 AM EDT, Aug 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,337
Open 12.46
Bid (Size) 11.96 (1)
Ask (Size) 12.72 (2)
Prev. Close 12.40
Today's Range 12.22 - 12.73
52wk Range 5.050 - 14.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
3 Psychedelic Stocks to Ride to the Moon and Beyond
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market. 
Via InvestorPlace
Exposures Product Safety

Performance

YTD
+137.38%
+137.38%
1 Month
+8.09%
+8.09%
3 Month
+6.28%
+6.28%
6 Month
+67.33%
+67.33%
1 Year
-10.25%
-10.25%

More News

Read More
Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns
Via InvestorPlace
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Via Talk Markets
GH Research: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
Via Talk Markets
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
GHRS Stock Earnings: GH Research Beats EPS for Q1 2024
Via InvestorPlace
GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD
Via Talk Markets
March Recap: Largest Psychedelic Drug Stocks Up Another 5%
Via Talk Markets
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week
Via Talk Markets
Exposures Product Safety
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
Via Talk Markets
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
Via Benzinga
GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
From GH Research PLC
Via GlobeNewswire
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
Via Talk Markets
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.